CD103+ DCs are a key population in the progression of non-alcoholic steatohepatitis: could DCs represent a novel therapeutic application in NASH?
2017
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI